Information Provided By:
Fly News Breaks for July 12, 2019
AXGN
Jul 12, 2019 | 09:33 EDT
Canaccord analyst Kyle Rose initiated AxoGen with a Buy rating and $32 price target. In a research note to investors, Rose says he believes the investments in the commercial team, market development initiatives and clinical trials position the company to reaccelerate growth into the second half of 2019. Rose says he feels the current valuation represents a compelling entry point, with top-line growth exceeding 30%, a strong balance sheet an an "exceptional" gross margin profile.
News For AXGN From the Last 2 Days
There are no results for your query AXGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.